Potential drawbacks of pharmacy-based COVID-19 testing

© Journal of Laboratory and Precision Medicine. All rights reserved. J Lab Precis Med 2021;6:10 | http://dx.doi.org/10.21037/jlpm-21-10 In a recent article, Risanger and colleagues have underpinned the potential benefits of establishing a pharmacy-based model of rapid diagnostic testing for coronavirus disease 2019 (COVD-19) (1). Although increasing and optimizing the access to diagnostic testing is a cornerstone in prevention and management of the ongoing severe acute respiratory disease coronavirus 2 (SARS-CoV-2) pandemic outbreak, we would like to briefly highlight some important caveats that may afflict a pharmacy-based strategy for replacing or supporting conventional laboratory-based SARS-CoV-2 diagnostic testing (2). The first aspect that needs to be highlighted, is that specimen self-collection by patients themselves does not provide the same diagnostic performance as collection by healthcare personnel, especially when patients have not been appropriately trained. Evidence of this has been provided in several studies, including that published by McCulloch et al. (3), who concluded that patient-collected nasopharyngeal swabs had 20% lower diagnostic sensitivity compared to clinician-collected specimens, especially when the viral load is low, but still clinically significant in terms of potential inter-human transmission. Similar results were reported by Tan et al. (4), who also showed that self-collection may be characterized by nearly 30% lower diagnostic sensitivity compared to collection by healthcare worker for specimens with cycle thresholds higher than 30. As there is now widespread literature highlighting the potential limitations (especially with respect to false negative test results) of self-collecting nasopharyngeal swabs (5), serious doubts remain as to the accuracy of this practice. A second aspect that needs to be highlighted is the testing technology used for diagnosing both symptomatic and (especially) asymptomatic COVID-19 infections. Rapid point of care (POC) molecular or antigenic assays do not provide comparable diagnostic performance as routine, laboratory-based, test, as clearly highlighted by the Cochrane COVID-19 Diagnostic Test Accuracy Group (6). In particular, rapid POC tests are still currently characterized by poor diagnostic sensitivity in identifying COVID-19 patients with low viral load (between 34–100% for rapid molecular tests and between 8–70% for rapid antigen tests, respectively), who are however important vehicles of viral transmission, accounting for nearly onefourth of all documented asymptomatic contagions (7). Insufficient quality assurance throughout the total POC testing process is another potential limitation (8). An international external quality assessment survey carried out for purpose of reviewing the quality of SARS-CoV-2 molecular detection has evidenced a considerably high coefficient of variation (i.e., between 35–54%) in terms of cycle threshold reporting across different clinical specimens (9). Thus, lack of establishing rigorous quality assessment schemes in all pharmacies providing COVID-19 diagnostics could end up generating poorly comparable or even unreliable data. Strict laboratory supervision of all decentralized testing practices, from test selection to results reporting, is unavoidable. On the other hand, resorting alternative strategies such as self-collected salivary samples (which allow less invasive and minimized hazard exposure) connected with molecular or laboratory-based antigen assays using high-sensitive chemiluminescent tracers, can be eventually envisaged for assuring better access to testing, while preserving adequate quality and reliability (10). A final concern relates to the need of receiving expert counselling on accuracy and clinical implications of this type of testing. This importance of this activity, which Editorial